Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.40 -0.93% 42.40 42.10 42.70 43.70 42.20 43.70 74,497 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.8 21.4 3.5 12.2 193

Ekf Diagnostics Share Discussion Threads

Showing 3501 to 3524 of 4500 messages
Chat Pages: Latest  144  143  142  141  140  139  138  137  136  135  134  133  Older
DateSubjectAuthorDiscuss
20/5/2021
07:17
Those who attended the AGM meeting will have noted why JB, in answer to a question, indicated why, on several important fronts, that the private sector partner is not ultimately regarded as a threat.

So, with that in mind it's worth considering the following excerpt from the AGM Statement -

One of the great strengths of our business has been the establishment of an enviable distribution network in Point-of-care and we believe we are well positioned to maximise the value of this network, both for existing and new EKF product deployments as well as after providing development services for white labelled third-party products, leveraging already strong customer relationships.
(End)

With the above in mind, the following makes for an interesting read, in terms of what a strong relationship with private sector partner could achieve -

What Amazon's potential move into at-home medical tests could mean for the market
by Heather Landi | May 19, 2021

Taking a look at Amazon's investments over the last few years, including its acquisition of PillPack and launch of Amazon Pharmacy, the focus on employer health, investments in home diagnostics due to the pandemic, and the announcement and expansion of Amazon Care, home testing and diagnostic lab services seems a likely area for Amazon to expand its healthcare ambitions, analysts say.

"Labs are a particularly good fit for the core strengths of Amazon. Distribution and supply chain, scale and cost advantage, and digital customer and patient engagement all pointed at reducing friction and likely ultimately improving use and access frequency," Nathan Ray, a director in the healthcare and life sciences practice at business and technology consulting firm West Monroe, told Fierce Healthcare.

Amazon also made a major move into the health wearables market with the launch of the Amazon Halo fitness tracker last year.

There is the potential for the tech giant to create synergies with its different healthcare plays, Michael Abrams, a managing partner at consulting firm Numerof & Associates, told Fierce Healthcare.

"The Halo device can monitor the vitals of someone with a chronic disease, Alexa can then remind them that it's time to make an appointment they can do a virtual visit and also get a test kit in the mail for lab testing. It's all very synergistic," he said.

Abrams added, "They are taking steps that are synergistic. Amazon Care is synergistic with Amazon Pharmacy and both of them would be synergistic with a diagnostics line of business as well."

A potential expansion into health diagnostics would represent the next phase of growth for Amazon's in-house COVID-19 testing lab as the threat of the COVID-19 pandemic diminishes. Business Insider reported that the company previously said it had spent "hundreds of millions of dollars" in building the lab.

"When Amazon puts a lot of money into something that has potential in the healthcare marketplace, they try it out with their employees and, if it works well, they take it public," Abrams said, noting the expansion of Amazon Care to other companies as an employee benefit.

Beyond COVID-19 testing, Amazon's potential move into diagnostics is most interesting in the broader employer space, Ray said.

"There is the potential to help employers receive better population-level information on their entire workforce including those that do not frequently engage with the health system. It could also be an interesting marketplace for new diagnostic test providers and even for your own physician to more easily and regularly order testing," he said.

This week, Amazon rolled out a new employee wellness program called WorkingWell, aimed at preventing injuries, providing wellness services, and offering quality healthcare for employees while at work and at home. By the end of 2021, WorkingWell will expand further to cover all of Amazon’s operations network in the U.S. with the aim of cutting recordable incident rates by 50 percent by 2025, the company announced in a press release.

A move into home diagnostics would put Amazon in direct competition with testing giants LabCorp and Quest as well as other at-home testing kit startups. Retailers such as Kroger, Walmart and Albertsons launched their own home-testing services for general consumers over the past year, Business Insider reported.

"I think we're on the verge of an explosion in at-home diagnostics, considering the new technologies out there," said Abrams.

He speculated that if Amazon jumped into the diagnostics space the company would take the same merchandising approach as with its other products by offering third-party lines and launching its own line of diagnostics.

"Existing players in the space might have to sell through Amazon’s platform and hoping that they don’t choose to come out with their own brand of at-home diagnostics. That’s a tough fight to win as it will drive margins down," he said.

Full story - hTTps://www.fiercehealthcare.com/tech/what-amazon-s-potential-move-into-at-home-medical-tests-could-mean-for-market

To my mind, EKF's development services for white labelled third-party products should sit very well in providing for certain private sector partners ambitions for own brand of at-home diagnostics.

wan
20/5/2021
06:26
Worthy of note today -

SourceBio International PLC National Framework contract
20/05/2021

SourceBio International accepted for UK-wide National Microbiology Framework (Lot 4) tender

and

Further COVID-19 Government testing approvals for Day 2 and Day 8 testing

Full release -
hTTps://uk.advfn.com/stock-market/london/sourcebio-SBI/share-news/SourceBio-International-PLC-National-Framework-con/85163761

wan
19/5/2021
21:06
How much are the Trellus shares going for, or is that about to be announced?
adobbing
19/5/2021
20:44
Draft Admission document here:

https://trellushealth.com/investors/

mirandaj
19/5/2021
20:09
ppmm, I didn't manage to dial in but have met Julian Baines many times and he's always been forthright and open - even after Stanbio acquisition and in a somewhat painful period for the company. So agree with your sentiments.

And I emailed the Trellus CFO and he emailed back (pretty quickly) confirming it is planned for tomorrow, so hopefully my ISA provider will be on the ball so I can participate in the restricted offer.

cisk
19/5/2021
19:49
I listened to the AGM today and have listened to a few of the companies i’m invested in or considering recently. The kind of detail regarding the business and future plans that EKF have willingly given I think is a shareholder is invaluable and resulted in the removal of any doubts during the recent selloff and helps plan my portfolio into the future.
ppmm
19/5/2021
19:41
Cisk, it says that information will be made available once the pricing and the raising of funds has been confirmed. That’s expected on 19th or shortly after. No information yet so may be tomorrow.
ppmm
19/5/2021
15:51
thanks ppmm, I'm out of the country at the moment so cannot access the investor section of trellus website... I've emailed them but not hopeful for a timely reply
cisk
19/5/2021
15:23
EKF are to be commended on their AGM statement today in terms of its clarity over a number of key areas - many others in the sector could learn from this.
nxc
19/5/2021
14:20
Yes, the process is set out on the investor section of the trellus website but the pricing and shares available are expected to be known some time today apparently
ppmm
19/5/2021
13:11
Does anyone know how to apply for extra trellus shares? Hold mine through ii isa so guess I have to go through them?
cisk
19/5/2021
11:29
The cannabidiol market is predicted to increase from $2.8 bn at a CAGR of 52.7% from 2020-2026 and I forgot that it was in fact referenced to EKF's new Purissima account win during a previous meeting (I checked my notes).


Background -
SAN FRANCISCO--(BUSINESS WIRE)-- Purissima, a health and wellness company, announced their launch today. Purissima has developed a bio-based ingredient platform technology that enables large-scale production and supply of natural, high-demand compounds currently derived from plant sources. Purissima partners with leading brands in the global health and wellness industry to provide pure, natural compounds and pharmaceuticals, made-to-order, at unprecedented commercial scale and economics for everyday personal care, consumer health and nutrition. The ingredients support overall health and nutrition, plus provide affordable, high-impact therapeutics for people suffering from a wide range of neurological and metabolic indications, chronic pain, inflammation, sleep disorders, cancer and other chronic conditions that impact most individuals at some point in their lifetimes.
hTTps://purissima.bio/wp-content/uploads/2019/11/Purissima-press-release-launch_November-14-FINAL-FINAL_2.pdf

Investors will note the reference to addressing a wide range of health related conditions, including chronic conditions (whether there is any read across to treating IBD remains to be seen).

wan
19/5/2021
11:16
Apologies, I think the new customer for synthetic cannabanoid may in fact be Purissima - hTTps://purissima.bio/

Nonetheless, Stepan is a very large new customer that I believe also requires large scale fermenters.

wan
19/5/2021
11:15
mginvestor - no, I heard him say 'week of 7th June if that's the Monday' (which it is).
sharw
19/5/2021
11:11
faz - yes, good points. I also found it encouraging that Julian Baines gave Mike Salter plus someone else the credit for the deal with the 'large customer'. 57% of revenue last year was in the US and that will probably increase sharply so I hope he doesn't get too much hiraeth.

I make no apology for use of the word alarming in relation to director movements because they always unsettle the market. Hence it is necessary to look carefully at them - there are often all sorts of reasons lurking in the background. The recent announcement of the departure of the CEO of Aveva (AVV) is one contributor to the 19% share price drop over the last month despite a really good replacement having been appointed.

sharw
19/5/2021
11:11
Just to add a bit more to what Faz said,

Mike, the incoming CEO, stated that the fermentation business is forecast (internally) to bring in revenues of £15m by 2024.

A question was asked as to whether Amazon could bring testing capabilities in-house and if they're worried that they could become a director competitor to EKF. Julian emphasised that they are not concerned. It looks like Amazon would much rather work with EKF due to their know-how in this area and totally rely on them. There are discussions to expand with the partner into home testing and more genomics works and enzyme manufacturing.

I thought it was interesting that they stated that the upgrades today were due to the core business growing rapidly.

Personally expect more upgrades as the year progresses.

Finally, did anyone get WC July as the roadshow week? I seemed to have misheard July instead of June.

Thanks

@mginvestor

mginvestor
19/5/2021
10:48
Faz...As previously covered by myself and Hastings (Martin Flitton on his Private Punter blog) the new fermenters will indeed be supporting the synthetic cannabanoid market, for which the new customer is Stepan, a two billion dollar turnover company that produces disinfectant for the healthcare market -

hTTps://www.stepan.com/content/stepan-dot-com/en/products-markets/Markets/household-institutional-industrial-cleaning.html

wan
19/5/2021
10:11
Well that was interesting! At the AGM, the major customer was all but named: 'I think we all know who it is' said JB; apparently their PR company is restricting the naming. Relationship is close and growing as the customer expands into home testing. WHat I particularly liked was bringng in the new CEO, Mike Salter, to emphasis how the core business was currently very strong- the chief reason for the trrading update - and and how it will grow. I just caught that one of the markets the new fermenters will be supporting is the synthetic cannabanoid industry. I'm sure some will be very interested in that potential. Mike Salter is Welsh, (well his accent is heavily Welsh anyway) and he spends one month in three over here. However the business is mainly done abroad - always has been (EKF was a German company and reversed into Admiral years ago to get onto AIM).

Trading update wc 7 June and a roadshow same week.

faz
19/5/2021
07:59
There was some chatter this week that Amazon were planning to start a full home diagnostics service. That could become very interesting for EKF
crazycoops
19/5/2021
07:50
Thanks Crazycoops. The Broker is aligning/maintaining the conservative line, and thus the backdrop of under promise and over delivery looks set to continue.

So it's also worth keeping an eye on the likely Private Sector Partner, where news continues to percolate out.

wan
19/5/2021
07:26
From N+1 Singer this morning, On the back of this, we upgrade our FY21 forecasts again (+8% to revenues and EBITDA) and see further potentially material upside to forecasts given the ongoing strength in the Covid-19 test kits business.
crazycoops
19/5/2021
07:23
"Alarming" is a ridiculous and absolutely erroneous description/use!
wan
19/5/2021
07:21
Richard Evans will be 65 in June next year. If they had used the word retirement it would not have made the board departures quite so alarming.
sharw
19/5/2021
07:18
So, we now have at least part of the reason for what is it that is making it confidentially restricted as to who EKF's private sector partner is....and who has massive plans too!
wan
Chat Pages: Latest  144  143  142  141  140  139  138  137  136  135  134  133  Older
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221128 06:21:05